These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10933749)

  • 41. Zinc and copper in the serum of diabetic patients.
    Car N; Car A; Granić M; Skrabalo Z; Momcilović B
    Biol Trace Elem Res; 1992; 32():325-9. PubMed ID: 1375073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.
    Suzuki T; Oba K; Futami S; Suzuki K; Ouchi M; Igari Y; Matsumura N; Watanabe K; Kigawa Y; Nakano H
    J Nippon Med Sch; 2006 Oct; 73(5):277-84. PubMed ID: 17106179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Optimal drug therapy of glucose intolerance is a guarantee of successful prevention of type 2 diabetes mellitus].
    Mkrtumian AM
    Ter Arkh; 2002; 74(12):86-9. PubMed ID: 12577852
    [No Abstract]   [Full Text] [Related]  

  • 44. Post-prandial carbohydrate modulation via gut--Indian perspective.
    Joshi SR
    J Assoc Physicians India; 2010 Nov; 58():665. PubMed ID: 21510457
    [No Abstract]   [Full Text] [Related]  

  • 45. Acarbose improved severe postprandial hypotension in a patient with diabetes mellitus.
    Sasaki E; Goda K; Nagata K; Kitaoka H; Ohsawa N; Hanafusa T
    J Diabetes Complications; 2001; 15(3):158-61. PubMed ID: 11358685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum levels of copper and zinc in newly diagnosed type-2 diabetic subjects.
    Ferdousi S; Mia AR
    Mymensingh Med J; 2012 Jul; 21(3):475-8. PubMed ID: 22828546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Acarbose for the treatment of impared glucose tolerance?].
    Carracedo E
    Gac Sanit; 2005; 19(3):265; author reply 265-6. PubMed ID: 15960964
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum mineral changes in alloxan diabetes before and after treatment with some hypoglycemic drugs.
    Halim D; Khalifa K; Awadalah R; El-Dessoukey EA; Hafez T; El-Hawary Z
    Z Ernahrungswiss; 1977 Mar; 16(1):39-43. PubMed ID: 404772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.
    Gu Y; Wang X; Li J; Zhang Y; Zhong H; Liu R; Zhang D; Feng Q; Xie X; Hong J; Ren H; Liu W; Ma J; Su Q; Zhang H; Yang J; Wang X; Zhao X; Gu W; Bi Y; Peng Y; Xu X; Xia H; Li F; Xu X; Yang H; Xu G; Madsen L; Kristiansen K; Ning G; Wang W
    Nat Commun; 2017 Nov; 8(1):1785. PubMed ID: 29176714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma zinc and copper in diabetes mellitus.
    Pidduck HG; Wren PJ; Evans DA
    Diabetes; 1970 Apr; 19(4):234-9. PubMed ID: 5437977
    [No Abstract]   [Full Text] [Related]  

  • 51. Association between antidiabetic agents use and leukocyte telomere shortening rates in patients with type 2 diabetes.
    Liu J; Ge Y; Wu S; Ma D; Xu W; Zhang Y; Yang Y
    Aging (Albany NY); 2019 Jan; 11(2):741-755. PubMed ID: 30694216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic effects of acarbose in young healthy men.
    Couet C; Ulmer M; Hamdaoui M; Bau HM; Debry G
    Eur J Clin Nutr; 1989 Mar; 43(3):187-96. PubMed ID: 2659314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term zinc supplementation in women with non-insulin-dependent diabetes mellitus: effects on plasma 5'-nucleotidase activities, insulin-like growth factor I concentrations, and lipoprotein oxidation rates in vitro.
    Blostein-Fujii A; DiSilvestro RA; Frid D; Katz C; Malarkey W
    Am J Clin Nutr; 1997 Sep; 66(3):639-42. PubMed ID: 9280186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.
    McCarty MF; DiNicolantonio JJ
    Open Heart; 2015; 2(1):e000205. PubMed ID: 25685364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing ulcerative colitis by increasing hydrogen production via oral administration of Acarbose.
    Zhu JH; Zhang DQ; Chen WC
    Afr J Tradit Complement Altern Med; 2013; 10(5):356-359. PubMed ID: 24311850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma zinc and copper in obesity and after intestinal bypass.
    Atkinson RL; Dahms WT; Bray GA; Jacob R; Sandstead HH
    Ann Intern Med; 1978 Oct; 89(4):491-3. PubMed ID: 697228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of synthetic corticosteroids on plasma zinc and copper levels in humans.
    Yunice AA; Czerwinski AW; Lindeman RD
    Am J Med Sci; 1981; 282(2):68-74. PubMed ID: 7325187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An assessment of the physiological significance of cimetidine interactions with copper and zinc in biofluids as based on the computer-simulated distribution of the involved complexes at therapeutic levels of the drug.
    Akrivos F; Blais MJ; Hoffelt J; Berthon G
    Agents Actions; 1984 Dec; 15(5-6):649-59. PubMed ID: 6532185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term use of acarbose and CV Event: confusing finding from mega data bank.
    Wu CH; Shen CJ; Wu KL; Sun ZJ; Chang MF; Chen JF; Tu ST
    Diabet Med; 2016 Dec; 33(12):1749-1750. PubMed ID: 27135277
    [No Abstract]   [Full Text] [Related]  

  • 60. Reply to 'Long-term use of acarbose and CV event: confusing finding from mega data bank'.
    Chang CH; Chang YC; Lin JW; Chuang LM
    Diabet Med; 2016 Dec; 33(12):1750-1751. PubMed ID: 27136450
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.